Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Polyploidy, aneuploidy and the evolution of cancer.

Merlo LM, Wang LS, Pepper JW, Rabinovitch PS, Maley CC.

Adv Exp Med Biol. 2010;676:1-13. Review.

PMID:
20687466
2.

Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS.

Am J Gastroenterol. 2001 Oct;96(10):2839-48.

3.

Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.

Chao DL, Maley CC, Wu X, Farrow DC, Galipeau PC, Sanchez CA, Paulson TG, Rabinovitch PS, Reid BJ, Spitz MR, Vaughan TL.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1935-40.

4.

Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression.

Doak SH, Jenkins GJ, Parry EM, Griffiths AP, Baxter JN, Parry JM.

Mutat Res. 2004 Mar 22;547(1-2):133-44.

PMID:
15013707
5.

Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.

Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ.

Am J Gastroenterol. 2009 Nov;104(11):2673-80. doi: 10.1038/ajg.2009.437. Epub 2009 Jul 28.

PMID:
19638963
6.

Early events during neoplastic progression in Barrett's esophagus.

Reid BJ.

Cancer Biomark. 2010;9(1-6):307-24. doi: 10.3233/CBM-2011-0162. Review.

7.

17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus.

Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, Rabinovitch PS, Reid BJ.

Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4.

8.

Barrett's esophagus: a model of human neoplastic progression.

Neshat K, Sanchez CA, Galipeau PC, Cowan DS, Ramel S, Levine DS, Reid BJ.

Cold Spring Harb Symp Quant Biol. 1994;59:577-83. Review. No abstract available.

PMID:
7587115
9.

p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.

Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, Reid BJ.

Cancer Res. 2001 Nov 15;61(22):8284-9.

11.

Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort.

Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS.

Gastroenterology. 1992 Apr;102(4 Pt 1):1212-9.

PMID:
1551528
12.

Barrett's oesophagus: from metaplasia to dysplasia and cancer.

Fléjou JF.

Gut. 2005 Mar;54 Suppl 1:i6-12. Review.

13.

Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.

Lomo LC, Blount PL, Sanchez CA, Li X, Galipeau PC, Cowan DS, Ayub K, Rabinovitch PS, Reid BJ, Odze RD.

Am J Surg Pathol. 2006 Apr;30(4):423-35.

PMID:
16625087
14.

Barrett's esophagus: ordering the events that lead to cancer.

Reid BJ, Barrett MT, Galipeau PC, Sanchez CA, Neshat K, Cowan DS, Levine DS.

Eur J Cancer Prev. 1996 Dec;5 Suppl 2:57-65. No abstract available.

PMID:
9061296
15.

Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.

Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ.

J Natl Cancer Inst. 1999 Dec 15;91(24):2087-95.

16.

Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.

Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ.

Oncogene. 1996 Nov 7;13(9):1867-73.

PMID:
8934532
17.

Biomarkers in Barrett's esophagus.

Reid BJ, Blount PL, Rabinovitch PS.

Gastrointest Endosc Clin N Am. 2003 Apr;13(2):369-97. Review.

PMID:
12916666
18.

Barrett's esophagus: a molecular perspective.

Spechler SJ.

Curr Gastroenterol Rep. 2005 Jun;7(3):177-81. Review.

PMID:
15913475
19.

DNA ploidy status and proliferative activity as markers of malignant potential in Barrett's esophagus: flow cytometric study using routinely paraffin-embedded tissue.

Giménez A, Minguela A, de Haro LM, Parrilla P, Bermejo J, Pérez D, García AM, Ortiz MA, Molina J, Alvarez R.

World J Surg. 2000 Jan;24(1):72-7.

PMID:
10594207
20.

Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.

Werther M, Saure C, Pahl R, Schorr F, Rüschoff J, Alles JU, Heinmöller E.

Pathol Res Pract. 2008;204(5):285-94. doi: 10.1016/j.prp.2007.12.011. Epub 2008 Mar 11.

PMID:
18337019

Supplemental Content

Support Center